Coronary Stenting

Spiral Bound | August 1, 2010

byAnthony Bavry, R. David Anderson, William Brearley

not yet rated|write a review
In the last twenty-five years, coronary stenting stands as the cornerstone of modern day interventional cardiology. Today many choices exist for interventionalists with the most basic delineation being bare metal stents (BMS) and drug eluting stents (DES). Within each broad category there aremultiple stent delivery systems, sizes, structural differences, various metal compositions, and anti-proliferative agents for drug eluting.There are several controversies currently surrounding coronary stents. Despite the fact that DES has been proven to decrease vessel restenosis when compared to bare metal stents, the first generation of DES increased the occurrence of late stent thrombosis, which was uncommon with bare metalstents. Additionally, stents have been used for multiple types of lesions with a significant number of these being considered off label indications. Lastly, the duration of dual anti-platelet therapy with aspirin and clopidogrel following stent implantation, especially DES, needs to be furtherexamined by the medical community. Despite current topics of debate in stenting, much promise exists in coronary intervention with bio-absorbable stents and anti-proliferative balloons currently in development. An understanding of the various principles of coronary stenting factors, including patient appropriateness, potential complications, and peri-operative management, is necessary for any healthcare provider currently treating cardiac patients. Perhaps most importantly, a firm understanding of theimportance of dual anti-platelet therapy can have a significant impact on the prevention of stent complications, especially stent thrombosis, which is often associated with significant mortality. This guide will serve as a reference for those healthcare providers who evaluate potential coronarystenting patients, as well as to help them properly manage those who are already stent recipients. Using the ultra-concise, portable format of the Oxford American Pocket Note series, this volume will prove to be a practical guide for interventionalists seeking a quick reference in coronarystenting.

Pricing and Purchase Info


Ships within 1-3 weeks
Ships free on orders over $25

From the Publisher

In the last twenty-five years, coronary stenting stands as the cornerstone of modern day interventional cardiology. Today many choices exist for interventionalists with the most basic delineation being bare metal stents (BMS) and drug eluting stents (DES). Within each broad category there aremultiple stent delivery systems, sizes, str...

Anthony A. Bavry, MD, MPH, is Associate Professor of Medicine in the Division of Cardiovascular Medicine at the University of Florida. R. David Anderson, M.D., is F.A.C.C. in the Division of Cardiovascular Medicine, Associate Professor of Medicine, and Director of Interventional Cardiology at the University of Florida. William Brearle...

other books by Anthony Bavry

Acute Coronary Syndromes in Clinical Practice
Acute Coronary Syndromes in Clinical Practice

Kobo ebook|Dec 16 2008

$33.79 online$43.87list price(save 22%)
Format:Spiral BoundDimensions:56 pages, 6.75 × 3.75 × 1 inPublished:August 1, 2010Publisher:Oxford University PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:0199732469

ISBN - 13:9780199732463

Look for similar items by category:


Extra Content

Table of Contents

1. IntroductionA brief history of the evolution of coronary stenting with an overview of stent classification, purpose of this guide, and future direction2. Stent ClassificationBare metal stents vs Drug eluting stentsBreifly discuss major meta-analyses and registries on the topicDescription of currently available stents3. Indications for Coronary RevascularizationCurrent indications for stenting (ie focal lesions, avoidance of bifurcation lesion, large vessels, non-diabetic patients, etc)Discussion of stenting in acute coronary syndromesRole of CABG versus DES for multi-vessel disease (SYNTAX trial)Discussion medical therapy for stable angina (COURAGE) and medical therapy for late presentation of myocardial infarction (OAT trial)4. Pre-catheterization AssessmentImportance of assessment of renal function, anemia and bleeding risks, co-morbidities, current medications which may need to be held or adjusted (metformin, insulin, etc)Also assessment of any future surgical procedures and determination of compliance for post PCI anti-platelet therapy and its potential contribution to stent complication/thrombosisChoice of intraprocedural anti-coagulation and anti-platelet therapyNeed for embolic protection, IABP, and transvenous pacingAccess site management5. Stent DeliverySizing and delivery basics with brief discussion of cardiac catheterization and stent delivery/deployment including available catheters, wires, etc.Discussion of adjunctive measures such as FFR (FAME trial) and IVUS to aid in lesion candidacy and stent guidance pre and post interventionMultiple illustrationsSpecial lesion setups: bifurcations, ostial lesions, heavily calcified lesions, vein grafts, left main6. Potential ComplicationsContrast nephropathy and other complications including bleeding (hematoma, vessel injury), MI/CVA, emergent coronary bypass, heart block, cardiac arrest, contrast nephropathyManagement of hypotension, hypertension, heart failure, and severe allergic reactionSpecific risk of various complications for patient discussion (table)Discussion of risk factors for in-stent restenosis as well as acute and late stent thrombosis with a focus on the inherent differences in presentation with each7. Medical TherapyMedical therapies including anti-platelet agents (including Prasugrel), beta blockers, statins, and ACE inhibitors in patients with coronary artery disease and coronary stentsOther potential modifiers of risk including diet, exercise, weight loss, and smoking cessationMaintenance anti-platelet therapy for different types of stents (BMS vs DES) and discussion of potential need for longer durationUse of aspirin, clopidogrel, and warfarin in patients with atrial fibrillation/mechanical heart valves/etc.8. Perioperative ManagementHigh risk periods following stent implantationPotential for IIb/IIa bridgingClopidogrel hold and re-initiation9. Current ControversiesIn stent restenosisAcute and late stent thrombosis with DES, off label use including vein grafts, duration of dual anti-platelet therapy and consequences of premature discontinuation10. Stress testing/surveillanceIndications for repeat heart catheterization, stress testing11. Future DevelopmentsBioabsorbable stents, new stent delivery systems, laser and atherectomy developments, imaging technology including CT angiogram12. Provider and Patient Resources13. References